July 12, 2016
1 min read
Save

FDA grants rare pediatric disease designation to ABT-414 for DIPG

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The FDA granted rare pediatric disease designation to ABT-414 for the treatment of children with epidermal growth factor receptor–amplified diffuse intrinsic pontine glioma.

Diffuse intrinsic pontine glioma (DIPG) — a highly aggressive and difficult-to-treat brain tumor located at the base of the brain — is the second most common malignant pediatric brain tumor, affecting approximately 200 to 400 children each year in the United States.

The designation was based on a proposed pediatric substudy “nested” within an ongoing phase 2 study of ABT-414 (AbbVie, Life Science Pharmaceuticals, Seattle Genetics) — an investigational antibody drug conjugate targeting EGFR — in adults with recurrent EGFR–amplified glioblastoma.

“Pediatric patients with high-grade gliomas have a rare and fatal disease. This rare pediatric designation, a first for AbbVie, is an important advancement as we continue to evaluate ABT-414 and its potential to help this group of patients who desperately need a new treatment option,” Gary Gordon, MD, vice president of oncology clinical development for AbbVie, said in a press release. “The proposal of including a nested cohort within an adult global trial is an endeavor that we hope may bring more treatments to pediatric patients.”

ABT-414 received orphan drug designation from the FDA for the treatment of adults with glioblastoma in 2014.